Active Filter(s):
Details:
ELE-Ket+ and ELE-Psilo+ are expected to enter Phase II clinical trials for the adjunctive treatment of major depressive disorder at the end of 2021. Under the terms of the agreement, Eleusis will acquire Kalypso and its intellectual property in an all-stock transaction.
Lead Product(s): ELE-Psilo+
Therapeutic Area: Psychiatry/Psychology Product Name: ELE-Psilo+
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Eleusis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 14, 2020